About SIGRIMA 420MG/14ML
Introducing SIGRIMA 420MG/14ML, a top-rated and first-rate anticancer solution for intravenous infusion. Featuring the eminent monoclonal antibody Pertuzumab at a concentration of 420 mg per 14 mL vial, SIGRIMA stands as a top-drawer choice for effective breast cancer treatment. It is recommended for adult patients, as directed by a physician, and comes in convenient English & Hindi packaging. With its clear "Open from here" guidance and instant checkout availability, SIGRIMA assures both ease-of-use and safety. Motto: For a Healthier Tomorrow.
SIGRIMA 420MG/14ML: Ideal for Adults, Targeted for Efficacy
SIGRIMA 420MG/14ML is exclusively suitable for adults as prescribed by physicians. Its specific use in the intravenous treatment of certain breast cancers underlines its targeted and general use as an anticancer agent. As a therapeutic monoclonal antibody in liquid concentrate form, SIGRIMA proves highly effective during the recommended use type-IV infusion. This ensures optimum delivery and benefit for patients seeking advanced cancer care solutions.
SIGRIMA 420MG/14ML - Payment Terms, FOB Port, and Sample Policy
We offer transparent payment terms, ensuring secure transactions for all SIGRIMA 420MG/14ML orders. The product is available for shipment from a specified FOB port, facilitating convenient freight handling in the export market. Our sample policy enables healthcare professionals and traders to evaluate SIGRIMA's market value before bulk purchasing, supporting informed business decisions and seamless integration into global healthcare supply chains.
FAQ's of SIGRIMA 420MG/14ML:
Q: How is SIGRIMA 420MG/14ML administered to patients?
A: SIGRIMA 420MG/14ML is administered through intravenous (IV) infusion as directed by a qualified physician. Each vial contains a concentrated liquid form of Pertuzumab, given under medical supervision in clinical or hospital settings.
Q: What are the storage requirements for SIGRIMA 420MG/14ML?
A: The vial should be stored below 30C and protected from light. Proper storage helps maintain the integrity and efficacy of the medication until administration.
Q: When should SIGRIMA 420MG/14ML be used during cancer treatment?
A: SIGRIMA is used as prescribed by an oncologist or treating physician, typically as part of a comprehensive breast cancer therapy regimen. Dosage schedules are determined based on patient needs and treatment protocols.
Q: Where is SIGRIMA 420MG/14ML packaging available and what languages are used?
A: SIGRIMA 420MG/14ML is distributed with packaging in both English and Hindi, catering to a diverse patient population in various healthcare settings.
Q: What is the primary therapeutic benefit of SIGRIMA 420MG/14ML?
A: SIGRIMA 420MG/14ML functions as an antineoplastic agent, specifically designed to target and treat certain types of breast cancer, thereby contributing to improved patient outcomes.